Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olinciguat Phase 1 MAD and Food Effect Study
NCT02792998Phase 1Completed
- Sponsor
- Cyclerion Therapeutics
- Start
- May 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of olinciguat in sickle cell disease (SCD) (3 arms), sponsored by Cyclerion Therapeutics. Primary endpoints: Treatment Emergent Adverse Event at 47 Days, Maximum observed plasma concentration at 47 Days and 3 more. Started May 2016; status: completed.
02
Drugs
olinciguat
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02792998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02792998.